Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Current Assets (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Current Assets readings, the most recent being $676.2 million for Q4 2025.

  • On a quarterly basis, Current Assets rose 33.97% to $676.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $676.2 million, a 33.97% increase, with the full-year FY2025 number at $676.2 million, up 33.97% from a year prior.
  • Current Assets hit $676.2 million in Q4 2025 for Amicus Therapeutics, up from $594.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $676.2 million in Q4 2025 to a low of $399.7 million in Q1 2023.
  • Median Current Assets over the past 5 years was $498.1 million (2022), compared with a mean of $506.2 million.
  • Biggest five-year swings in Current Assets: decreased 29.51% in 2022 and later skyrocketed 33.97% in 2025.
  • Amicus Therapeutics' Current Assets stood at $596.8 million in 2021, then decreased by 28.99% to $423.8 million in 2022, then rose by 13.98% to $483.1 million in 2023, then increased by 4.49% to $504.7 million in 2024, then soared by 33.97% to $676.2 million in 2025.
  • The last three reported values for Current Assets were $676.2 million (Q4 2025), $594.1 million (Q3 2025), and $538.0 million (Q2 2025) per Business Quant data.